Wall Street Zen Upgrades Organon & Co. (NYSE:OGN) to “Buy”

Organon & Co. (NYSE:OGN) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other research firms also recently issued reports on OGN. Morgan Stanley lowered their target price on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. JPMorgan Chase & Co. lowered their price objective on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a research note on Tuesday, November 11th. Piper Sandler downgraded Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price objective for the company. in a report on Monday, October 27th. Finally, Barclays assumed coverage on Organon & Co. in a research report on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $8.38.

Organon & Co. Stock Performance

Organon & Co. stock opened at $7.25 on Friday. The firm has a market capitalization of $1.88 billion, a P/E ratio of 3.77, a PEG ratio of 1.50 and a beta of 0.58. The stock has a fifty day moving average price of $7.16 and a 200 day moving average price of $8.89. Organon & Co. has a 52 week low of $6.18 and a 52 week high of $17.23. The company has a current ratio of 1.75, a quick ratio of 1.20 and a debt-to-equity ratio of 9.69.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Monday, November 10th. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.93 by $0.08. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.During the same period last year, the company earned $1.38 EPS. Equities research analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in OGN. GAMMA Investing LLC grew its holdings in Organon & Co. by 22.4% during the 2nd quarter. GAMMA Investing LLC now owns 5,645 shares of the company’s stock valued at $55,000 after purchasing an additional 1,034 shares in the last quarter. Maryland State Retirement & Pension System increased its position in shares of Organon & Co. by 1.4% during the second quarter. Maryland State Retirement & Pension System now owns 88,420 shares of the company’s stock worth $856,000 after acquiring an additional 1,195 shares during the last quarter. Rexford Capital Inc. boosted its holdings in Organon & Co. by 14.9% in the third quarter. Rexford Capital Inc. now owns 11,380 shares of the company’s stock valued at $122,000 after purchasing an additional 1,480 shares during the last quarter. Amalgamated Bank increased its holdings in Organon & Co. by 1.9% during the 3rd quarter. Amalgamated Bank now owns 79,805 shares of the company’s stock worth $852,000 after purchasing an additional 1,514 shares during the last quarter. Finally, Integrated Wealth Concepts LLC boosted its stake in shares of Organon & Co. by 2.8% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock valued at $626,000 after buying an additional 1,594 shares during the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.